Exubera, the first and so far only commercially available inhaled-insulin diabetes treatment, is on the verge of turning into an expensive flop for its maker, Pfizer.
At one point, the company regarded the drug as a potential blockbuster. But despite six months of marketing to doctors, Exubera receives only about one of every 500 prescriptions for insulin written in the United States.
"I don't think the drug can be saved," said David Risinger, an analyst at Merrill Lynch, who last week cut his estimates for Exubera sales. Risinger now expects that Exubera will have $310 million in sales worldwide in 2012, down from his previous estimate of $800 million.
Other analysts have also cut their forecasts.
More
No comments:
Post a Comment